Clinical Trials · NCT07391267
Pathogenesis of Chronic Kidney Disease Associated With Metabolic Dysfunction- Associated Fatty Liver Disease (MAFLD) and Treatment Response of Oral Semaglutide.
- Phase
- N/A
- Recruitment status
- Not Yet Recruiting
- Sponsor
- Institute of Liver and Biliary Sciences, India
- Enrollment
- 90
- Start date
- Feb 2026
- Locations
- 1 site, India
- Primary endpoint
- Time to first occurrence of a composite primary outcome event defined as persistent eGFR decline of greater than or equal to 50 percentage from trial start, reaching ESRD, death from kidney disease or death from cardiovascular disease.